Acute Admitted Multimorbid PatientsPL-IMMNCT07159932
Poland Integrated Medicines Management (PL-IMM) - Study Assessing the Provision of Complex Clinical Pharmacy Services to Hospitalized Patients
A study testing multidisciplinary treatment in people with Acute Admitted Multimorbid Patients, run by Wroclaw Medical University at 1 site in Poland.
Trial summary
The aim of the study is to assess whether the involvement of a clinical pharmacist in patient care at every stage of hospitalization, from admission to discharge, will improve the quality of healthcare services provided in clinical and economic terms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Admitted Multimorbid Patients
- What is being tested?
- multidisciplinary treatment
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 610 participants
- Where
- 1 sitePoland
- Study dates
- 1 Jan 2026to 30 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients meeting the following inclusion criteria:
- ≥18 years old and an acute admission to the hospital fulfilling at least one of the following criteria:
- taking ≥4 medicines
- taking high risk medicines listed in the medicines reconciliation standard of Polish Society of Clinical Pharmacy (….)
- medicine related admission to the hospital within last 12 months
- chronic kidney or liver disease
- after solid organ transplantation
Who cannot join
- age below 18 years old
- pregnancy
- resident of long-term care facility
- unable to express informed consent to participate in the research
- expected survival less than 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Poland Integrated Medicines Management (PL-IMM) - Randomized Controlled Trial Assessing the Provision of Complex Clinical Pharmacy Services to Hospitalized Patients in the Polish Healthcare System
The aim of the study is to assess whether the involvement of a clinical pharmacist in patient care at every stage of hospitalization, from admission to discharge, will improve the quality of healthcare services provided in clinical and economic terms. As part of the research study, we will randomly assign you to two different groups.
Within one group, a pharmacist will be involved in the process of caring for you throughout your hospital stay. The pharmacist will participate in medical rounds, verify medications upon admission to the hospital, check current test results and medical orders regarding pharmacotherapy, verify medications upon discharge and provide advice on the use of medications. All activities will be carried out in consultation with other medical staff. The aim is to check whether such a model of patient care increases safety and leads to improved pharmacotherapy for patients, and also has a positive effect on patient satisfaction and compliance with therapeutic recommendations. Additionally, the opinion of the medical staff and the economic aspects of this solution will be assessed. Within the second group, you will receive standard care offered by the hospital. In the case of both groups, after the hospitalization is completed, the pharmacist will contact you after 1, 3, 6 months to verify your health condition - he or she will ask about any hospitalizations, complications, side effects, and additional visits to the doctor.
Read the detailed description
Despite the benefits of clinical pharmacy services demonstrated in numerous publications and their implementation in many countries around the world, Poland has still not achieved nationwide implementation. There is also a lack of scientific data at the national level showing the benefits of including a pharmacist in the patient facing activities. Therefore, this RCT aimes to determine if pharmacist input at each stage of hospitalization, from admission to discharge, can result in an enhanced level of patient care when compared to standard care as measured by a number of clinical and economic outcomes. Given the aforementioned, the objective of this research is to:
- Primary outcome: Determine the incidence of hospital, emergency department and other unscheduled visits after discharge from hospital during the 6 months follow-up period.
- Secondary outcome: Assess the length of stay (LoS) in hospital.
- Additional outcomes:
- Evaluate the service by determining the frequency and type of interventions performed, their acceptance and influence on the quality of pharmacotherapy.
- Assess the perception of the service by patients.
- Assess the perception of the service by healthcare professionals.
- Estimate the potential financial benefits of the service.
- Conditions
- Acute Admitted Multimorbid Patients
- Being tested
- multidisciplinary treatment
- Keywords
- clinical pharmacy, integrated medicines managment, pharmacist interventions, clinical pharmacy services, medicines management, transfer of care, medicines review, medicines reconcilliation, patient education
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
multidisciplinary treatmentBehavioural
The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information
| Study group | Role | What they receive |
|---|---|---|
| Control group | No intervention | Standard care during hospital stay, without pharmacist involved |
| Pharmacist intervention - IMM | Experimental | A pharmacist is included in the multidisciplinary treatment team during the hospital stay Receives: Behavioral: multidisciplinary treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Additional episodes of care
incidence of hospital, emergency department and other unscheduled visits after discharge from hospital during the 6 months follow-up period
Measured: 1, 3 and 6 months after discharge
Secondary outcomes (1)
LoS
the length of stay (LoS) in hospital
Measured: Periprocedural
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start1 Jan 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Admitted Multimorbid PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 610 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Wroclaw Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kamila Urbańczyk, Wroclaw Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07159932
- Sponsor's protocol ID
- KB 47O/2O23N
- Acronym
- PL-IMM
- Status last verified
- Jun 2025
- First submitted
- 24 Jun 2025
- Last updated
- 8 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Poland Integrated Medicines Management (PL-IMM) - Randomized Controlled Trial Assessing the Provision of Complex Clinical Pharmacy Services to Hospitalized Patients in the Polish Healthcare System
- ClinicalTrials.gov ID
- NCT07159932
- Acronym / sponsor ID
- PL-IMM / KB 47O/2O23N
- Conditions
- Acute Admitted Multimorbid Patients
- Keywords
- clinical pharmacy, integrated medicines managment, pharmacist interventions, clinical pharmacy services, medicines management, transfer of care, medicines review, medicines reconcilliation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 610 participants (estimated)
- Lead sponsor
- Wroclaw Medical UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to assess whether the involvement of a clinical pharmacist in patient care at every stage of hospitalization, from admission to discharge, will improve the quality of healthcare services provided in clinical and economic terms. As part of the research study, we will randomly assign you to two different groups.
Within one group, a pharmacist will be involved in the process of caring for you throughout your hospital stay. The pharmacist will participate in medical rounds, verify medications upon admission to the hospital, check current test results and medical orders regarding pharmacotherapy, verify medications upon discharge and provide advice on the use of medications. All activities will be carried out in consultation with other medical staff. The aim is to check whether such a model of patient care increases safety and leads to improved pharmacotherapy for patients, and also has a positive effect on patient satisfaction and compliance with therapeutic recommendations. Additionally, the opinion of the medical staff and the economic aspects of this solution will be assessed. Within the second group, you will receive standard care offered by the hospital. In the case of both groups, after the hospitalization is completed, the pharmacist will contact you after 1, 3, 6 months to verify your health condition - he or she will ask about any hospitalizations, complications, side effects, and additional visits to the doctor.
Detailed description
Despite the benefits of clinical pharmacy services demonstrated in numerous publications and their implementation in many countries around the world, Poland has still not achieved nationwide implementation. There is also a lack of scientific data at the national level showing the benefits of including a pharmacist in the patient facing activities. Therefore, this RCT aimes to determine if pharmacist input at each stage of hospitalization, from admission to discharge, can result in an enhanced level of patient care when compared to standard care as measured by a number of clinical and economic outcomes. Given the aforementioned, the objective of this research is to:
- Primary outcome: Determine the incidence of hospital, emergency department and other unscheduled visits after discharge from hospital during the 6 months follow-up period.
- Secondary outcome: Assess the length of stay (LoS) in hospital.
- Additional outcomes:
- Evaluate the service by determining the frequency and type of interventions performed, their acceptance and influence on the quality of pharmacotherapy.
- Assess the perception of the service by patients.
- Assess the perception of the service by healthcare professionals.
- Estimate the potential financial benefits of the service.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control group | No intervention | –Standard care during hospital stay, without pharmacist involved |
| Pharmacist intervention - IMM | Experimental | Behavioral: multidisciplinary treatmentA pharmacist is included in the multidisciplinary treatment team during the hospital stay |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- ≥18 years old and an acute admission to the hospital fulfilling at least one of the following criteria:
- taking ≥4 medicines
- taking high risk medicines listed in the medicines reconciliation standard of Polish Society of Clinical Pharmacy (….)
- medicine related admission to the hospital within last 12 months
- chronic kidney or liver disease
Key exclusion criteria (5 listed)
- age below 18 years old
- pregnancy
- resident of long-term care facility
- unable to express informed consent to participate in the research
- expected survival less than 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| multidisciplinary treatmentThe pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information | Behavioural | Pharmacist intervention - IMM |
Primary outcome
Additional episodes of care
Time frame: 1, 3 and 6 months after discharge
incidence of hospital, emergency department and other unscheduled visits after discharge from hospital during the 6 months follow-up period
1 secondary outcome
LoS
Time frame: Periprocedural
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2025.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing multidisciplinary treatment in people with Acute Admitted Multimorbid Patients, run by Wroclaw Medical University at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kamila Urbańczyk, MPharm (0048 71 32 70 427, kamila.urbanczyk@umw.edu.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Additional episodes of care (time frame: 1, 3 and 6 months after discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2025.